Please login to the form below

Not currently logged in
Email:
Password:

Combination treatment

This page shows the latest Combination treatment news and features for those working in and with pharma, biotech and healthcare.

Roche scores EU approval twice for Tecentriq in lung cancer

Roche scores EU approval twice for Tecentriq in lung cancer

Tecentriq has been approved as a first-line treatment option in both indications, in combination with chemotherapy. ... However, MSD is closing the gap, with a current phase 3 trial (KeyNote-604) testing Keytruda in combination with chemotherapy as a

Latest news

  • MSD’s Keytruda catches up in kidney cancer MSD’s Keytruda catches up in kidney cancer

    Combination therapy approved in EU for all risk groups. MSD’s Keytruda in combination with Inlyta (axitinib) has won European Commission (EC) approval in the first-line treatment of the most ... The European approval of Keytruda with axitinib

  • Tecentriq approved in Europe for triple negative breast cancer Tecentriq approved in Europe for triple negative breast cancer

    Roche can dominate in niche setting. Roche has gained EU-wide approval for Tecentriq in combination with chemotherapy as a treatment for patients with metastatic PD-L1 positive triple negative breast ... The scale of those revenues will very much depend

  • Imbruvica gains expanded use in Europe Imbruvica gains expanded use in Europe

    Roche) for the treatment of adult patients with Waldenström's macroglobulinemia (a type of lymphoma). ... cancer. It is currently approved in Europe for the treatment of CLL as a single agent or in combination for the treatment of adult patients who

  • Keytruda now available for untreated metastatic lung cancer patients via Cancer Drugs Fund Keytruda now available for untreated metastatic lung cancer patients via Cancer Drugs Fund

    In addition to this, the watchdog reported uncertainty around the Keytruda combination therapy meeting the criteria for being considered a life-extending treatment at the end of life in comparison to ... Pembrolizumab combination therapy is a promising

  • HIV meeting hears progress towards vaccine and cure HIV meeting hears progress towards vaccine and cure

    Hope for global treatment. While combination treatment regimens have transformed the prospects for people with HIV, an effective preventive vaccine or cure remains elusive. ... induce immune activation and potentially lead to viral remission, as part of

More from news
Approximately 0 fully matching, plus 242 partially matching documents found.

Latest Intelligence

  • Deal Watch April 2016 Deal Watch April 2016

    Another deal worth pondering about is the $265m exclusive license by AstraZeneca (AZ) of the approved Zurampic (lesuranid) plus a fixed dose combination with allopurinol for treatment of gout. ... 85 . Dong A (SK). Tobira (US). Cross license. Evogliptin

  • Pharma deals in April 2015 Pharma deals in April 2015

    No deal terms were disclosed. The initial development plan will look at the combination therapy as a potential treatment for NHL.  . ... The treatment combines an antibody engineered to target CD19 with the cancer-killing agent maytansinoid.

  • Pharma deals during July 2014 Pharma deals during July 2014

    Underscoring its strategy in focusing the business in the core areas, in July Baxter also announced the acquisition of AesRx, a private US company developing a phase II stage prophylactic treatment ... The acquisition of Almirall's respiratory business

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    And again, matching drugs that work well together will be crucial going forward: “Combination treatment will be a critical component; how best to put these drugs together with other checkpoint inhibitors, ... This includes people with NSCLC who have a

  • The rise of chronic disease in BRIC markets The rise of chronic disease in BRIC markets

    First-line treatment in China combines surgery and chemotherapy for 24.5 per cent of patients. ... In China there has been a rise in the use of Xeloda in combination with docetaxel as a second and third-line treatment.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

  • Oncosec

    body.  OncoSec has built a deep and diverse clinical pipeline utilizing TAVO as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; ... Results from recently completed

  • Marketing strategy in complex environments

    The last few years have seen influential scientific advances, resulting in subtle shifts in how pharma tackles disease treatment. ... The treatment of aggressive diseases often benefits very noticeably from combination therapy, especially when involving

  • Raising Awareness: It’s World COPD Day today!

    Inhaled corticosteroids (ICS)  are another COPD treatment used to reduce inflammation in the lungs. ... Overuse of inhaled corticosteroids? The treatment guidelines set out by GOLD (1) have suggested that an ICS should only be prescribed after single

More from PMHub
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...

Latest intelligence

Alzheimers incidence
A roadmap to the successful treatment of Alzheimer’s disease
Building on past research to learn more about the disease and how to treat it...
Article: Like, Like, Like: Harnessing the power of social media insights
...
Its Know Your Numbers week
Do you know yours?...

Infographics